3 not yet recruiting, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 3, Recruiting 1 |
Follow Pirtobrutinib: new trials by email Literature Review of Pirtobrutinib trials Research Report on Pirtobrutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement pirtobrutinib+MTX+immunolchemotherapy - Pirtobrutinib, Immunochemotherapy | Phase 2 | Not yet recruiting | Pengpeng Xu | 24 | 2026-09-01 | 2026-09-11 |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Pirtobrutinib+Pola-R-CHP - DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 48 | 2026-07-31 | 2026-08-06 |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Pirtobrutinib plus R-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 34 | 2026-07-30 | 2026-08-06 |
| Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma Thiotepa, Pirtobrutinib , Sintilimab(TPS) - Pirtobrutinib, Sintilimab | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 24 | 2026-02-10 | 2026-02-18 |
Dendritic Cell Sarcoma, Interdigitating (3)
Hemic and Lymphatic Diseases (3) · Histiocytic Disorders, Malignant (3) · Histiocytosis (3) · Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3)
pirtobrutinib (2) · Thiotepa (1) · sintilimab (1)
Changzhou No.2 People's Hospital (2) · Pengpeng Xu (1) · Zhejiang Cancer Hospital (1)
China (4)
Haiyan Yang, MD (1)